Publication: Angiofibroma of soft tissue: Current status of pathology and genetics
Authors
Nakayama, Shizuhide ; Nishio, Jun ; Aoki, Mikiko ; Koga, Kaori ; Nabeshima, Kazuki ; Yamamoto, Takuaki
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-444
item.page.type
info:eu-repo/semantics/article
Description
Abstract
y. Angiofibroma of soft tissue (AFST) is a new
soft tissue tumor entity described in the 2020 World
Health Organization Classification of Soft Tissue and
Bone Tumors. It most often arises in the lower
extremities of middle-aged adults and pursues a benign
clinical course with a low rate of non-destructive local
recurrence. Histologically, the lesion consists of uniform
bland spindle cells in a fibromyxoid stroma with a
prominent vascular network. The vascular component
forms a complex arrangement of small, thin-walled
branching blood vessels. By immunohistochemistry,
AFST is variably positive for epithelial membrane
antigen, desmin, smooth muscle actin, CD34, CD68,
CD163 and estrogen receptor. The exact etiology of
AFST remains unknown, but it appears genetically
distinct, with a balanced t(5;8)(p15;q13) translocation
resulting in a fusion of aryl hydrocarbon receptor
repressor (AHRR) and nuclear receptor coactivator 2
(NCOA2). Knowledge of this recently described entity is
important because it can mimic a variety of intermediate
and malignant soft tissue tumors, including solitary
fibrous tumor, low-grade fibromyxoid sarcoma, myxoid
liposarcoma and low-grade myxofibrosarcoma. We
review AFST, with an emphasis on the diagnostic
spectrum, recent molecular genetic features and the
differential diagnosis.
publication.page.subject
Citation
Histology and Histopathology Vol. 37, nº8 (2022)
item.page.embargo
Ir a EstadÃsticas
Este Ãtem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/